experiments demonstrate that, when combined with immune checkpoint blockade (ICB) therapy, HCFCMP not only significantly inhibits primary tumor growth but also effectively suppresses distant tumor progression. This substantially improves the immunotherapeutic response rate and provides a promising strategy for addressing tumor metastasis and recurrence.
Li et al. (Fri,) studied this question.